Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Background Cabozantinib has shown clinical activity in combination with checkpoint
inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab …

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are
prevalent liver conditions that underlie the development of life-threatening cirrhosis, liver …

Introduction Hepatocellular carcinoma (HCC) represents the sixth most commonly
diagnosed malignancy worldwide, accounting for millions of deaths annually. Despite …

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …